Immunocore Kimmtrak Achieves 16% Five-Year Survival Rate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IMCR?
Immunocore announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, prospective Phase 3 randomized trial in patients with unresectable or metastatic uveal melanoma - a disease with a very poor prognosis and a historical survival rate of less than 5% at 5 years. Kimmtrak doubled the likelihood of being alive at five years, with an OS for Kimmtrak of 16% versus 8% in the control arm. These results also represent the longest follow-up reported for any T cell engager in a solid tumor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCR
Wall Street analysts forecast IMCR stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 31.460
Low
37.00
Averages
64.56
High
100.00
Current: 31.460
Low
37.00
Averages
64.56
High
100.00
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Significant Survival Improvement: KIMMTRAK demonstrated a five-year survival rate of 16% in a randomized trial of 378 patients, doubling the rate compared to the control group, indicating its potential to redefine treatment standards for metastatic uveal melanoma.
- Long-Term Follow-Up Data: This study provides the longest survival follow-up data, with a median overall survival of 21.6 months for KIMMTRAK compared to 16.9 months for the control group, showcasing its durable efficacy and enhancing physician confidence in discussing long-term survival with patients.
- Treatment Response Analysis: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression, achieving a tumor reduction rate of 27% compared to just 4% in the control group, suggesting that KIMMTRAK may offer better survival opportunities even after disease progression.
- Prognostic Factor Impact: The study confirmed that the survival benefit of KIMMTRAK was significant even in patients with known poor prognostic factors, such as high tumor burden and extrahepatic disease, further solidifying its position as a first-line treatment and potentially offering hope to more patients.
See More
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Survival Rate Improvement: KIMMTRAK has achieved a five-year survival rate of 16% in HLA-A*02:01 positive metastatic uveal melanoma patients, doubling the rate of the control group, demonstrating its significant impact on patient prognosis.
- Clinical Trial Data: In a randomized trial involving 378 patients, the median overall survival for the KIMMTRAK group was 21.6 months, significantly surpassing the 16.9 months observed in the control group, indicating the drug's potential in extending survival.
- Treatment Continuation: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression compared to only 25% in the control group, highlighting the drug's tolerability and the willingness of patients to continue therapy.
- Prognostic Factor Impact: KIMMTRAK demonstrated survival benefits even in patients with known poor prognostic factors such as high tumor burden and elevated LDH, further solidifying its position as a first-line treatment.
See More
Immunocore (IMCR) Q4 2025 Earnings Call Transcript
See More
Immunocore Q4 Earnings Report Analysis
- Disappointing Earnings: Immunocore reported a Q4 GAAP EPS of -$0.60, missing expectations by $0.42, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Although revenue increased by 24.3% year-over-year to $104.48 million, it fell short of expectations by $3.29 million, reflecting intensified market competition and a need for strategic adjustments in sales.
- Strong Cash Reserves: As of December 31, 2025, Immunocore held $864.2 million in cash, cash equivalents, and marketable securities, ensuring ample funding for future R&D and operations, thereby enhancing financial stability.
- Uncertain Market Outlook: Immunocore's presentation at the J.P. Morgan Healthcare Conference garnered attention, yet the current financial data may lead to diminished investor confidence regarding its future growth prospects.
See More
Immunocore Set to Announce Q4 Earnings on February 25
- Earnings Announcement: Immunocore (IMCR) is scheduled to release its Q4 earnings on February 25 before the market opens, with investors keenly awaiting the results to gauge the company's growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.20, reflecting a 57.4% year-over-year increase, indicating significant improvement in profitability despite remaining in negative territory.
- Revenue Expectations: The consensus revenue estimate is $107.77 million, representing a 28.2% year-over-year growth, highlighting a positive trend in market demand and product sales for Immunocore.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and one downward adjustment, indicating analyst divergence regarding the company's financial outlook.
See More
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
See More
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Significant Survival Improvement: KIMMTRAK demonstrated a five-year survival rate of 16% in a randomized trial of 378 patients, doubling the rate compared to the control group, indicating its potential to redefine treatment standards for metastatic uveal melanoma.
- Long-Term Follow-Up Data: This study provides the longest survival follow-up data, with a median overall survival of 21.6 months for KIMMTRAK compared to 16.9 months for the control group, showcasing its durable efficacy and enhancing physician confidence in discussing long-term survival with patients.
- Treatment Response Analysis: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression, achieving a tumor reduction rate of 27% compared to just 4% in the control group, suggesting that KIMMTRAK may offer better survival opportunities even after disease progression.
- Prognostic Factor Impact: The study confirmed that the survival benefit of KIMMTRAK was significant even in patients with known poor prognostic factors, such as high tumor burden and extrahepatic disease, further solidifying its position as a first-line treatment and potentially offering hope to more patients.
See More
KIMMTRAK Doubles Five-Year Survival Rate for Metastatic Uveal Melanoma Patients
- Survival Rate Improvement: KIMMTRAK has achieved a five-year survival rate of 16% in HLA-A*02:01 positive metastatic uveal melanoma patients, doubling the rate of the control group, demonstrating its significant impact on patient prognosis.
- Clinical Trial Data: In a randomized trial involving 378 patients, the median overall survival for the KIMMTRAK group was 21.6 months, significantly surpassing the 16.9 months observed in the control group, indicating the drug's potential in extending survival.
- Treatment Continuation: In the KIMMTRAK group, 57% of patients continued treatment beyond disease progression compared to only 25% in the control group, highlighting the drug's tolerability and the willingness of patients to continue therapy.
- Prognostic Factor Impact: KIMMTRAK demonstrated survival benefits even in patients with known poor prognostic factors such as high tumor burden and elevated LDH, further solidifying its position as a first-line treatment.
See More
Immunocore (IMCR) Q4 2025 Earnings Call Transcript
See More
Immunocore Q4 Earnings Report Analysis
- Disappointing Earnings: Immunocore reported a Q4 GAAP EPS of -$0.60, missing expectations by $0.42, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Although revenue increased by 24.3% year-over-year to $104.48 million, it fell short of expectations by $3.29 million, reflecting intensified market competition and a need for strategic adjustments in sales.
- Strong Cash Reserves: As of December 31, 2025, Immunocore held $864.2 million in cash, cash equivalents, and marketable securities, ensuring ample funding for future R&D and operations, thereby enhancing financial stability.
- Uncertain Market Outlook: Immunocore's presentation at the J.P. Morgan Healthcare Conference garnered attention, yet the current financial data may lead to diminished investor confidence regarding its future growth prospects.
See More
Immunocore Set to Announce Q4 Earnings on February 25
- Earnings Announcement: Immunocore (IMCR) is scheduled to release its Q4 earnings on February 25 before the market opens, with investors keenly awaiting the results to gauge the company's growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.20, reflecting a 57.4% year-over-year increase, indicating significant improvement in profitability despite remaining in negative territory.
- Revenue Expectations: The consensus revenue estimate is $107.77 million, representing a 28.2% year-over-year growth, highlighting a positive trend in market demand and product sales for Immunocore.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and one downward adjustment, indicating analyst divergence regarding the company's financial outlook.
See More
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
See More
